Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: A mirror image retrospective study.

[1]  D. Cattaneo,et al.  Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance , 2020, Pharmacopsychiatry.

[2]  Kamyar Keramatian,et al.  Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review , 2019, CNS Drugs.

[3]  S. Gentile.  Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update , 2018, Hormone molecular biology and clinical investigation.

[4]  M. Broder,et al.  Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder. , 2018, Journal of comparative effectiveness research.

[5]  A. Tanskanen,et al.  Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder , 2018, JAMA psychiatry.

[6]  L. Marshall,et al.  Bipolar disorders , 2018, Nature Reviews Disease Primers.

[7]  J. Calabrese,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder , 2018, Bipolar disorders.

[8]  J. Calabrese,et al.  Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. , 2018, Journal of affective disorders.

[9]  N. Nikolić,et al.  The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting , 2017, International clinical psychopharmacology.

[10]  J. Calabrese,et al.  Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. , 2017, The Journal of clinical psychiatry.

[11]  S. Chakrabarti.  Treatment-adherence in bipolar disorder: A patient-centred approach , 2016, World journal of psychiatry.

[12]  Chi-Shin Wu,et al.  Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. , 2016, Journal of affective disorders.

[13]  P. Chue,et al.  A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder , 2016, Therapeutics and clinical risk management.

[14]  A. Altamura,et al.  Paliperidone Palmitate Depot in the Long-term Treatment of Psychotic Bipolar Disorder: A Case Series , 2015, Clinical neuropharmacology.

[15]  Chia‐Fen Tsai,et al.  A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder , 2015, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[16]  P. Llorca,et al.  What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? , 2014, Nordic journal of psychiatry.

[17]  P. Courtet,et al.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness , 2013, BMC Psychiatry.

[18]  S. Montgomery,et al.  A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder , 2012, European Neuropsychopharmacology.

[19]  B. Lafer,et al.  Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder , 2012, CNS Drugs.

[20]  D. Bond,et al.  Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes , 2011, International clinical psychopharmacology.

[21]  Y. Jing,et al.  One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis , 2011, BMC psychiatry.

[22]  R. Shelton,et al.  Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder , 2010, Expert review of neurotherapeutics.

[23]  L. Alphs,et al.  A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. , 2009, Bipolar disorders.

[24]  D. Bond,et al.  Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients , 2008, International clinical psychopharmacology.

[25]  E. Vieta,et al.  A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[26]  Michael Berk,et al.  Bipolar disorder , 2006, The Lancet.

[27]  M. Sajatovic,et al.  Treatment adherence with antipsychotic medications in bipolar disorder. , 2006, Bipolar disorders.

[28]  A. Nierenberg,et al.  Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. , 2006, Psychiatric services.

[29]  Jan Scott,et al.  Treatment non‐adherence in affective disorders , 2002, Acta psychiatrica Scandinavica.